Setting the TEMPO: A phase 3 program to investigate tavapadon, a selective D1/D5 partial agonist, for Parkinson’s disease
| Autor: | Fernandez, H.F., Pfister, S.P., Leoni, M., Berry, M., Gangadharan, A., Duvvuri, S., Parker, J., Wang, S., Briscoe, R.B., Sanchez, R. |
|---|---|
| Zdroj: | In Parkinsonism and Related Disorders August 2023 113 Supplement |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect